EcoR1 Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsARCH Venture PartnersSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation EndeavorsLeaps by Bayer+5 more
.png)
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsPacific Channel3E Bioventures CapitalARCH Venture PartnersGeneral CatalystLeaps by BayerMaverick Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.